Search results for "MBQ-167"

showing 1 items of 1 documents

Physiologically-Based Pharmacokinetic/Pharmacodynamic Model of MBQ-167 to Predict Tumor Growth Inhibition in Mice

2020

MBQ-167 is a dual inhibitor of the Rho GTPases Rac and Cdc42 that has shown promising results as an anti-cancer therapeutic at the preclinical stage. This drug has been tested in vitro and in vivo in metastatic breast cancer mouse models. The aim of this study is to develop a physiologically based pharmacokinetic/pharmacodynamic (PBPK-PD) model of MBQ-167 to predict tumor growth inhibition following intraperitoneal (IP) administration in mice bearing Triple Negative and HER2+ mammary tumors. PBPK and Simeoni tumor growth inhibition (TGI) models were developed using the Simcyp V19 Animal Simulator. Our developed PBPK framework adequately describes the time course of MBQ-167 in each of the mo…

Physiologically based pharmacokinetic modellinglcsh:RS1-441Pharmaceutical ScienceSpleenPharmacologyArticlelcsh:Pharmacy and materia medica03 medical and health sciences0302 clinical medicinebreast cancerPharmacokineticsIn vivomedicinePotency030304 developmental biology0303 health sciencesMammary tumorbusiness.industryMBQ-167medicine.diseaseMetastatic breast cancermedicine.anatomical_structure030220 oncology & carcinogenesisPharmacodynamicsRac inhibitorphysiologically based pharmacokinetic modelingbusinessPharmaceutics
researchProduct